CPMD on OTC
CANNAPHARMARX, INC.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with BeyondSpring Inc., Northwest Biotherapeutics or AVENUE THERAPEUTICS, INC., or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
-153.1%Gross margin3
-245.8%Operating margin3
-817.2%Net margin3
66.1%Revenue growth, 20253
-$794.6KFree cash flow3
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue64¢$3.4M
- Interest36¢$2.0M
Out of $1.4M in revenue.3 The company lost money this year.
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | $1.4M | $820.1K |
| Cost of goods sold | $3.4M | $3.8M |
| Gross loss | -$2.1M | -$2.9M |
| General and administrative | $489.6K | $145.7K |
| Payroll and consulting fees | $0 | $114.8K |
| Professional fees | $469.7K | $435.5K |
| Royalty expense | $303.5K | $0 |
| Total operating expenses | $1.3M | $696.0K |
| Loss from operations | -$3.3M | -$3.6M |
| Change in the fair value of derivative conversion feature | -$850.2K | $105.1K |
| Change in the fair value of obligation to issue shares | $1.5M | -$3.4M |
| Foreign exchange gain | $66.3K | $24.7K |
| Interest expense | -$2.0M | -$2.3M |
| Imputed interest expense | -$490.6K | $0 |
| Loss on the extinguishment of debt | $0 | -$690.7K |
| Loss on impairment of investment | -$4.5M | $0 |
| Gain on write-off of accounts payable and accrued liabilities | $410.4K | $0 |
| Other expense | -$1.9M | $0 |
| Total other expenses | -$7.8M | -$6.3M |
| Net loss | -$11.1M | -$9.9M |
| Foreign currency translation adjustment | -$612.3K | $591.2K |
| Net comprehensive loss | -$11.7M | -$9.3M |
| Basic and diluted loss per share of common shares | -$0.02 | -$0.02 |
| Weighted average number of shares outstanding | 662.5M shares | 625.3M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2024-02-29 |
|---|---|---|---|
| Cash | $1.8K | $2.2K | |
| Goods and services tax receivable | $29.8K | $18.7K | |
| Accounts receivable | $164.4K | $1.7K | |
| Inventory | $1.1M | $996.2K | |
| Total current assets | $1.3M | $1.0M | |
| Equipment, net | $127.0K | $137.2K | |
| Right-of-use building, net | $5.6M | $5.2M | |
| Investments | $0 | $4.5M | |
| Total assets | $7.0M | $10.8M | |
| Accounts payable and accrued liabilities | $10.1M | $9.3M | |
| Accrued interest | $1.7M | $2.5M | |
| Deferred revenue | $260.6K | $0 | |
| Notes payable | $482.7K | $6.7M | |
| Convertible notes | $1.0M | $1.3M | |
| Derivative conversion feature | $2.0M | $1.2M | |
| Loans payable to related parties, current portion | $12.6M | $462.8K | |
| Royalty payable | $305.5K | $0 | |
| Liability for right-of-use building, current portion | $1.0M | $728.2K | |
| Obligation to issue shares | $2.2M | $3.7M | |
| Total current liabilities | $31.6M | $25.8M | |
| Loans payable to related parties | $548.6K | $0 | |
| Liability for right-of-use building | $5.0M | $4.9M | |
| Total liabilities | $37.2M | $30.6M | |
| Common shares, $0.0001 par value; 5,000,000,000 shares authorized, 662,501,405 issued and outstanding as at December 31, 2025 and 2024 | $66.2K | $66.2K | |
| Shares to be issued | $1.6K | $0 | |
| Treasury shares | $623 | $623 | |
| Additional paid-in capital | $81.5M | $80.1M | |
| Accumulated deficit | -$112.3M | -$101.2M | |
| Accumulated other comprehensive (loss) income | -$56.7K | $555.6K | |
| Total shareholders' deficit | -$30.2M | -$19.8M | |
| Total liabilities and shareholders' deficit | $7.0M | $10.8M | |
| Common Stock, Shares Par Value | $0.00 | $0.00 | |
| Common Stock, Shares Authorized | 5.0B shares | 5.0B shares | |
| Common Stock, Shares Issued | 662.5M shares | 662.5M shares | 4.9M shares |
| Common Stock, Shares Outstanding | 662.5M shares | 662.5M shares | |
| Treasury stock, shares | 6.2M shares | 6.2M shares | |
| Treasury stock, par value | $0.00 | $0.00 | |
| Preferred Stock, Shares Authorized | 3.2M shares | ||
| Preferred Stock Shares Outstanding | 629.4K shares | 629.4K shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$11.1M | -$9.9M |
| Loss on impairment of inventory included in cost of goods sold | $2.0M | $1.9M |
| Shares to be issued for services included in general and administrative | $142.8K | $0 |
| Change in the fair value of derivative conversion feature | $850.2K | -$105.1K |
| Change in the fair value of obligation to issue shares | -$1.5M | $3.4M |
| Foreign exchange gain | -$66.3K | $0 |
| Interest expense | $2.0M | $2.3M |
| Imputed interest expense | $490.6K | $0 |
| Loss on the extinguishment of debt | $0 | $690.7K |
| Loss on impairment of investment | $4.5M | $0 |
| Gain on write-off of accounts payable and accrued liabilities | -$410.4K | |
| Other expense | $1.9M | $0 |
| Goods and services tax receivable | -$11.1K | $42.8K |
| Accounts receivable | -$1.0M | -$1.7K |
| Inventory | -$2.0M | -$508.1K |
| Royalty payable | $303.5K | $0 |
| Accounts payable and accrued liabilities | $2.9M | $763.6K |
| Deferred revenue | $260.6K | $0 |
| Accrued interest | $0 | -$272.4K |
| Cash used in operating activities | -$789.1K | -$1.7M |
| Purchase of equipment | -$5.5K | $0 |
| Cash used in investing activities | -$5.5K | $0 |
| Proceeds from notes payable | $0 | $1.5M |
| Proceeds from loans payable to related parties | $794.3K | $0 |
| Proceeds from convertible notes | $0 | $150.0K |
| Cash provided by financing activities | $794.3K | $1.7M |
| Net change in cash | -$352 | $1.5K |
| Cancellation of preferred shares Series B | $0 | $2.0M |
| Conversion of convertible loans into common shares | $0 | $20.4K |
| Conversion of preferred shares Series A into common shares | $0 | $1.2K |
| Cash received by related parties directly from customers | $819.9K | $0 |
| Cash paid by related parties directly to suppliers | $2.1M | $0 |
| Reclassification of notes payable to loans payable to related parties | $6.8M | $0 |
| Reclassification of convertible notes to loans payable to related parties | $281.1K | $0 |
| Adjustment for related party loan modification included in additional paid-in capital | $1.3M | $0 |
Former names
Recent filings
- Aug 18, 202610-Q FORM 10-Q FOR JUN 2026
- Aug 17, 2026NT 10-Q
- May 20, 202610-Q
- May 18, 2026NT 10-Q
- Mar 31, 202610-K
- Jan 13, 20268-K
- Dec 18, 20258-K
- Nov 14, 202510-Q
- Oct 10, 20258-K
- Aug 22, 2025144
- Aug 14, 202510-Q
- May 22, 2025144
- May 16, 2025NT 10-Q
- May 16, 202510-Q
- May 6, 20258-K
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11